Literature DB >> 15670188

Increasing urine albumin excretion is associated with growth hormone hypersecretion and reduced clearance of insulin in adolescents and young adults with type 1 diabetes: the Oxford Regional Prospective Study.

Rakesh Amin1, Rachel M Williams, January Frystyk, Margot Umpleby, David Matthews, Hans Orskov, R Neil Dalton, David B Dunger.   

Abstract

HYPOTHESIS: We previously described lower insulin-like growth factor I (IGF-I) levels in association with increased microalbuminuria (MA) risk in type 1 diabetic subjects followed from diabetes diagnosis through puberty into adulthood. By inference lower IGF-I levels may be associated with higher GH levels and changes in insulin sensitivity.
METHODS: To test this hypothesis, microalbuminuric subjects (MA+, n = 14) from the same cohort had overnight GH levels measured during euglycaemia (5 mmol/l, 01:00-07:30 h) maintained by a variable rate insulin infusion followed by a 2-step hyperinsulinaemic, euglycaemic clamp study using [6.6 2H2] glucose, and were compared to MA- controls (MA-, n = 14), matched for age (median 19.3 years, range 15.8-30.5), sex, duration of diabetes (11.1 years, range 5.1-16.4).
RESULTS: In MA+ cases GH levels, measured by the Pulsar programme, were higher (baseline; 1.8 +/- 1.4 vs. 0.7 +/- 0.5 ng/ml, P = 0.02, mean; 3.8 +/- 1.3 vs. 2.6 +/- 1.6 ng/ml, P = 0.03, maximum; 16.7 +/- 7.0 vs. 12.3 +/- 5.4, P = 0.02), despite similar HbA1(c) levels (9.8%vs. 9.6%, P = 0.6) and body or truncal fat mass. Fourier transform revealed increased GH pulse amplitude at all periodicities and overnight insulin clearance was reduced (11.7 +/- 6.9 vs. 20.1 +/- 6.5 ml/kg/min, P < 0.02). In multiple regression analysis, urine albumin excretion was associated with higher GH levels and reduced insulin clearance, independent of HbA1(c) and body composition. In female cases (n = 9), dextrose requirements were reduced during the first step of the euglycaemic clamp (1.7 +/- 0.8 vs. 2.7 +/- 1.4, P < 0.05) but no such differences existed in males or in the rate of glucose production or disposal.
CONCLUSION: The development of MA during puberty and young adulthood is associated with higher GH levels and abnormalities in insulin metabolism, particularly in females. These data extend support for our previous findings indicating a role for the GH/IGF-I axis in the pathogenesis of MA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670188     DOI: 10.1111/j.1365-2265.2005.02185.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Occurrence of microalbuminuria in young people with Type 1 diabetes: importance of age and diabetes duration.

Authors:  C R Alleyn; L K Volkening; J Wolfson; A Rodriguez-Ventura; J R Wood; L M B Laffel
Journal:  Diabet Med       Date:  2010-05       Impact factor: 4.359

2.  Longitudinal relation between limited joint mobility, height, insulin-like growth factor 1 levels, and risk of developing microalbuminuria: the Oxford Regional Prospective Study.

Authors:  R Amin; T K Bahu; B Widmer; R N Dalton; D B Dunger
Journal:  Arch Dis Child       Date:  2005-10       Impact factor: 3.791

Review 3.  The glomerular podocyte as a target of growth hormone action: implications for the pathogenesis of diabetic nephropathy.

Authors:  P Anil Kumar; Frank C Brosius; Ram K Menon
Journal:  Curr Diabetes Rev       Date:  2011-01

4.  The development of microalbuminuria is associated with raised longitudinal adiponectin levels in female but not male adolescent patients with type 1 diabetes.

Authors:  R Amin; J Frystyk; K Ong; R N Dalton; A Flyvbjerg; D B Dunger
Journal:  Diabetologia       Date:  2008-07-12       Impact factor: 10.122

Review 5.  Diabetic nephropathy in children and adolescents.

Authors:  Radovan Bogdanović
Journal:  Pediatr Nephrol       Date:  2007-10-17       Impact factor: 3.714

6.  Neurodevelopmental Disorders, Glycemic Control, and Diabetic Complications in Type 1 Diabetes: a Nationwide Cohort Study.

Authors:  Shengxin Liu; Ralf Kuja-Halkola; Henrik Larsson; Paul Lichtenstein; Jonas F Ludvigsson; Ann-Marie Svensson; Soffia Gudbjörnsdottir; Magnus Tideman; Eva Serlachius; Agnieszka Butwicka
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.